Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.

Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K.

J Ovarian Res. 2013 May 11;6(1):35. doi: 10.1186/1757-2215-6-35.

2.

Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Free Radic Biol Med. 2010 May 1;48(9):1228-35. doi: 10.1016/j.freeradbiomed.2010.02.009. Epub 2010 Feb 12.

3.

Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity.

Kálai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K.

J Med Chem. 2011 Aug 11;54(15):5414-21. doi: 10.1021/jm200353f. Epub 2011 Jul 6.

PMID:
21702507
4.

Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties.

Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2010 Nov 15;10(10):1027-32. doi: 10.4161/cbt.10.10.13250. Epub 2010 Nov 15.

6.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

7.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
8.

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.

[No authors listed]

Drugs R D. 2006;7(5):317-28. Review.

PMID:
16922593
9.

Promising new developments in cancer chemotherapy.

Ferrante K, Winograd B, Canetta R.

Cancer Chemother Pharmacol. 1999;43 Suppl:S61-8. Review.

PMID:
10357561
10.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

11.

HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.

Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.

Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.

PMID:
22801507
12.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

PMID:
21885917
13.

Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

Montopoli M, Ragazzi E, Froldi G, Caparrotta L.

Cell Prolif. 2009 Apr;42(2):195-206. doi: 10.1111/j.1365-2184.2009.00585.x. Epub 2009 Feb 18.

PMID:
19236381
14.
15.

Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.

Viale M, Pastrone I, Pellecchia C, Vannozzi MO, Cafaggi S, Esposito M.

Anticancer Drugs. 1998 Jun;9(5):457-63.

PMID:
9660544
16.
17.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
18.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
19.

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2000 May;6(5):2053-63.

20.

Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T cells in peritoneal space.

Kim JE, Jang MJ, Lee JI, Chung YH, Jeong JH, Hung CF, Kim D.

J Immunother. 2012 Jan;35(1):1-13. doi: 10.1097/CJI.0b013e3182328569.

PMID:
22130157
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk